Literature DB >> 6440482

Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa.

K Takahashi, H Kanno.   

Abstract

The effects of antibiotic combinations against Pseudomonas aeruginosa infections frequently found in hospitalized patients were investigated. By means of an agar plate dilution checkerboard method, combinations of piperacillin-fosfomycin, cefoperazone-fosfomycin, and cefsulodin-fosfomycin were synergistic against 80.0, 85.0, and 82.6% of the strains tested. The mean fractional inhibitory concentration indices of piperacillin-fosfomycin, cefoperazone-fosfomycin, and cefsulodin-fosfomycin were 0.48, 0.42, and 0.46, respectively. The synergistic activities of these combinations were enhanced by the addition of a small amount of tobramycin, 0.25 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6440482      PMCID： PMC180018          DOI： 10.1128/AAC.26.5.789

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aeruginosa.

Authors:  E R Pavillard; H Miles
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  In-vitro activity of cefoperazone and penicillins alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  J A Hoogkamp-Korstanje; C M Pot; N A Westerdaal
Journal:  J Antimicrob Chemother       Date:  1981-08       Impact factor: 5.790

4.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

5.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.

Authors:  W M McCrae; J A Raeburn; E J Hanson
Journal:  J Infect Dis       Date:  1976-08       Impact factor: 5.226

7.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  C Watanakunakorn
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

10.  Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  P K Yu; R S Edson; J A Washington; P E Hermans
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191
  10 in total
  5 in total

1.  Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.

Authors:  G Samonis; S Maraki; D E Karageorgopoulos; E K Vouloumanou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-31       Impact factor: 3.267

2.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

Review 3.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

4.  In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius.

Authors:  Matthew DiCicco; Suresh Neethirajan; J Scott Weese; Ameet Singh
Journal:  BMC Microbiol       Date:  2014-05-19       Impact factor: 3.605

5.  Fosfomycin tromethamine. Antibiotic of choice in the female patient: A multicenter study.

Authors:  Abdul Rouf Khawaja; Farzana Bashir Khan; Tanveer Iqbal Dar; Arif Hameed Bhat; Mohd Saleem Wani; Baldev Singh Wazir
Journal:  Cent European J Urol       Date:  2015-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.